Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | LATS1 | O95835 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4043685 | 0.80 | HTR2C (0.40) | DHFRLATS1ADORA1ADORA2AHTR2C | |
| SCHEMBL4252649 | 0.79 | CHUK (0.46) | LATS1ADORA1ADORA2AHTR2C | |
| SCHEMBL4560012 | 0.78 | DHFR (0.52) | DHFRLMNAADORA1ADORA2A | |
| SCHEMBL3433512 | 0.73 | CHRNB2 (0.51) | LMNA | |
| SCHEMBL4302053 | 0.73 | ALDH1A1 (0.43) | LATS1ADORA2AHTR2C | |
| SCHEMBL4043686 | 0.72 | DHFR (0.41) | DHFRLATS1HTR2C | |
| SCHEMBL24375329 | 0.72 | ALOX5AP (0.41) | LATS1HTR2CALOX5APFEN1 | |
| SCHEMBL28855356 | 0.72 | ALOX5AP (0.41) | LATS1HTR2CALOX5APFEN1 | |
| SCHEMBL6329724 | 0.72 | ALDH1A1 (0.64) | LMNALATS1HTR2C | |
| SCHEMBL5787049 | 0.72 | ALDH1A1 (0.64) | LMNALATS1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009046416-A1 | ANILINOPYRIMIDINES AS JAK KINASE INHIBITORS | TARGEGEN INC. (US) | 2009-04-09 | — | — | WO | claimed |
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | PYGM, CKMT1A; CKMT1B, SMN1; SMN2 | DHFR 2912/4885LMNA 206/4885LATS1 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.